Metabolic inflammation-differential modulation by dietary constituents

Nutrients

Volumn 8, Issue 5, 2016, Pages

  Lyons, Claire L ^a   Kennedy, Elaine B ^a   Roche, Helen M ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Adipose tissue; Diet; Fatty acids; Insulin resistance; Liver; Metabolic inflammation; Muscle; Nutrition; Pancreas

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ABC TRANSPORTER A1; CD36 ANTIGEN; CD38 ANTIGEN; GLUCAGON LIKE PEPTIDE 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 6; MANNOSE RECEPTOR; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOUNSATURATED FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; POLYUNSATURATED FATTY ACID; PROTEIN KINASE C BETA; SATURATED FATTY ACID; SIRTUIN 1; STAT3 PROTEIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE;

ADIPOSE TISSUE; CD8+ T LYMPHOCYTE; DIET SUPPLEMENTATION; GENE EXPRESSION REGULATION; HUMAN; HYPERGLYCEMIA; IMMUNOMODULATION; INFLAMMATION; INFLAMMATORY INFILTRATE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRACELLULAR SIGNALING; LIPID DIET; LIPID METABOLISM; MACROPHAGE ACTIVATION; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OBESITY; OXYGEN CONSUMPTION; PANCREAS ISLET BETA CELL; REVIEW; WEIGHT REDUCTION; ADVERSE EFFECTS; DIET; DRUG EFFECTS; GENETICS; METABOLISM;

ADIPOSE TISSUE; CYTOKINES; DIET; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; OBESITY;

EID: 85012839337     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu8050247     Document Type: Review

References (122)

1. Gregor, M.F.; Hotamisligil, G.S. Inflammatory mechanisms in obesity. Annu. Rev. Immunol. 2011, 29, 415-445. [CrossRef] [PubMed]
2. Van Herpen, N.A.; Schrauwen-Hinderling, V.B. Lipid accumulation in non-adipose tissue and lipotoxicity. Physiol. Behav. 2008, 94, 231-241. [CrossRef] [PubMed]
3. Krahmer, N.; Farese, R.V.; Walther, T.C. Balancing the fat: Lipid droplets and human disease. EMBO Mol. Med. 2013, 5, 973-983. [CrossRef] [PubMed]
4. Servier Medical Art. Available online: http://www.servier.fr/servier-medical-art (accessed on 15 January 2016).
5. Stienstra, R.; Joosten, L.A.B.; Koenen, T.; van Tits, B.; van Diepen, J.A.; van den Berg, S.A.A.; Rensen, P.C.N.; Voshol, P.J.; Fantuzzi, G.; Hijmans, A.; et al. The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab. 2010, 12, 593-605. [CrossRef] [PubMed]
6. Finucane, O.M.; Lyons, C.L.; Murphy, A.M.; Reynolds, C.M.; Klinger, R.; Healy, N.P.; Cooke, A.A.; Coll, R.C.; McAllan, L.; Nilaweera, K.N.; et al. Monounsaturated fatty acid-enriched high-fat diets impede adipose NLRP3 inflammasome-mediated IL-1β secretion and insulin resistance despite obesity. Diabetes 2015, 64, 2116-2128. [CrossRef] [PubMed]
7. Liu, J.; Divoux, A.; Sun, J.; Zhang, J.; Clément, K.; Glickman, J.N.; Sukhova, G.K.; Wolters, P.J.; Du, J.; Gorgun, C.Z.; et al. Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nat. Med. 2009, 15, 940-945. [CrossRef] [PubMed]
8. Nishimura, S.; Manabe, I.; Nagasaki, M.; Eto, K.; Yamashita, H.; Ohsugi, M.; Otsu, M.; Hara, K.; Ueki, K.; Sugiura, S.; et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat. Med. 2009, 15, 914-920. [CrossRef] [PubMed]
9. Schipper, H.S.; Prakken, B.; Kalkhoven, E.; Boes, M. Adipose tissue-resident immune cells: Key players in immunometabolism. Trends Endocrinol. Metab. 2012, 23, 407-415. [CrossRef] [PubMed]
10. Cinti, S. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J. Lipid Res. 2005, 46, 2347-2355. [CrossRef] [PubMed]
11. Weisberg, S.P.; McCann, D.; Desai, M.; Rosenbaum, M.; Leibel, R.L.; Ferrante, A.W. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Investig. 2003, 112, 1796-1808. [CrossRef] [PubMed]
12. Xu, H.; Barnes, G.T.; Yang, Q.; Tan, G.; Yang, D.; Chou, C.J.; Sole, J.; Nichols, A.; Ross, J.S.; Tartaglia, L.A.; et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Investig. 2003, 112, 1821-1830. [CrossRef] [PubMed]
13. Kamei, N.; Tobe, K.; Suzuki, R.; Ohsugi, M.;Watanabe, T.; Kubota, N.; Ohtsuka-Kowatari, N.; Kumagai, K.; Sakamoto, K.; Kobayashi, M.; et al. Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J. Biol. Chem. 2006, 281, 26602-26614. [CrossRef] [PubMed]
14. Khan, I.M.; Perrard, X.-Y.; Brunner, G.; Lui, H.; Sparks, L.M.; Smith, S.R.;Wang, X.; Shi, Z.-Z.; Lewis, D.E.; Wu, H.; et al. Intermuscular and perimuscular fat expansion in obesity correlates with skeletal muscle T cell and macrophage infiltration and insulin resistance. Int. J. Obes. 2015, 39, 1607-1618. [CrossRef] [PubMed]
15. Morinaga, H.; Mayoral, R.; Heinrichsdorff, J.; Osborn, O.; Franck, N.; Hah, N.; Walenta, E.; Bandyopadhyay, G.; Pessentheiner, A.R.; Chi, T.J.; et al. Characterization of distinct subpopulations of hepatic macrophages in HFD/obese mice. Diabetes 2015, 64, 1120-1130. [CrossRef] [PubMed]
16. Reynolds, C.M.; McGillicuddy, F.C.; Harford, K.A.; Finucane, O.M.; Mills, K.H.G.; Roche, H.M. Dietary saturated fatty acids prime the NLRP3 inflammasome via TLR4 in dendritic cells-implications for diet-induced insulin resistance. Mol. Nutr. Food Res. 2012, 56, 1212-1222. [CrossRef] [PubMed]
17. Feuerer, M.; Herrero, L.; Cipolletta, D.; Naaz, A.; Wong, J.; Nayer, A.; Lee, J.; Goldfine, A.B.; Benoist, C.; Shoelson, S.; et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat. Med. 2009, 15, 930-939. [CrossRef] [PubMed]
18. Cancello, R.; Henegar, C.; Viguerie, N.; Taleb, S.; Poitou, C.; Rouault, C.; Coupaye, M.; Pelloux, V.; Hugol, D.; Bouillot, J.-L.; et al. Reduction of Macrophage Infiltration and Chemoattractant Gene Expression Changes in White Adipose Tissue of Morbidly Obese Subjects after Surgery-InducedWeight Loss. Diabetes 2005, 54, 2277-2286. [CrossRef] [PubMed]
19. Lumeng, C.N.; Bodzin, J.L.; Saltiel, A.R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Investig. 2007, 117, 175-184. [CrossRef] [PubMed]
20. Chan, K.L.; Pillon, N.J.; Sivaloganathan, D.M.; Costford, S.R.; Liu, Z.; Théret, M.; Chazaud, B.; Klip, A. Palmitoleate Reverses High Fat-induced Proinflammatory Macrophage Polarization via AMP-activated Protein Kinase (AMPK). J. Biol. Chem. 2015, 290, 16979-16988. [CrossRef] [PubMed]
21. Kratz, M.; Coats, B.R.; Hisert, K.B.; Hagman, D.; Mutskov, V.; Peris, E.; Schoenfelt, K.Q.; Kuzma, J.N.; Larson, I.; Billing, P.S.; et al. Metabolic dysfunction drives a mechanistically distinct proinflammatory phenotype in adipose tissue macrophages. Cell Metab. 2014, 20, 614-625. [CrossRef] [PubMed]
22. McGillicuddy, F.C.; Harford, K.A.; Reynolds, C.M.; Oliver, E.; Claessens, M.; Mills, K.H.G.; Roche, H.M. Lack of interleukin-1 receptor I (IL-1RI) protects mice from high-fat diet-induced adipose tissue inflammation coincident with improved glucose homeostasis. Diabetes 2011, 60, 1688-1698. [CrossRef] [PubMed]
23. Hotamisligil, G.; Shargill, N.; Spiegelman, B. Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance. Science 1993, 259, 87-91. [CrossRef] [PubMed]
24. Suganami, T.; Tanimoto-Koyama, K.; Nishida, J.; Itoh, M.; Yuan, X.; Mizuarai, S.; Kotani, H.; Yamaoka, S.; Miyake, K.; Aoe, S.; et al. Role of the Toll-like receptor 4/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler. Thromb. Vasc. Biol. 2007, 27, 84-91. [CrossRef] [PubMed]
25. Shi, H.; Kokoeva, M.V.; Inouye, K.; Tzameli, I.; Yin, H.; Flier, J.S. TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin. Investig. 2006, 116, 3015-3025. [CrossRef] [PubMed]
26. Hotamisligil, G.S.; Budavari, A.; Murray, D.; Spiegelman, B.M. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J. Clin. Investig. 1994, 94, 1543-1549. [CrossRef] [PubMed]
27. Wen, H.; Gris, D.; Lei, Y.; Jha, S.; Zhang, L.; Huang, M.T.-H.; Brickey,W.J.; Ting, J.P.-Y. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat. Immunol. 2011, 12, 408-415. [CrossRef] [PubMed]
28. Vandanmagsar, B.; Youm, Y.-H.; Ravussin, A.; Galgani, J.E.; Stadler, K.; Mynatt, R.L.; Ravussin, E.; Stephens, J.M.; Dixit, V.D. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat. Med. 2011, 17, 179-188. [CrossRef] [PubMed]
29. Koenen, T.B.; Stienstra, R.; van Tits, L.J.; Joosten, L.A.B.; van Velzen, J.F.; Hijmans, A.; Pol, J.A.; van der Vliet, J.A.; Netea, M.G.; Tack, C.J.; et al. The inflammasome and caspase-1 activation: A new mechanism underlying increased inflammatory activity in human visceral adipose tissue. Endocrinology 2011, 152, 3769-3778. [CrossRef] [PubMed]
30. Jeong, H.W.; Hsu, K.C.; Lee, J.-W.; Ham, M.; Huh, J.Y.; Shin, H.J.; Kim, W.S.; Kim, J.B. Berberine suppresses proinflammatory responses through AMPK activation in macrophages. Am. J. Physiol. Endocrinol. Metab. 2009, 296, E955-E964. [CrossRef] [PubMed]
31. Weldon, S.M.; Mullen, A.C.; Loscher, C.E.; Hurley, L.A.; Roche, H.M. Docosahexaenoic acid induces an anti-inflammatory profile in lipopolysaccharide-stimulated human THP-1 macrophages more effectively than eicosapentaenoic acid. J. Nutr. Biochem. 2007, 18, 250-258. [CrossRef] [PubMed]
32. Oliver, E.; McGillicuddy, F.C.; Harford, K.A.; Reynolds, C.M.; Phillips, C.M.; Ferguson, J.F.; Roche, H.M. Docosahexaenoic acid attenuates macrophage-induced inflammation and improves insulin sensitivity in adipocytes-specific differential effects between LC n-3 PUFA. J. Nutr. Biochem. 2012, 23, 1192-1200. [CrossRef] [PubMed]
33. Anthony, J.S.; Karnovskyi, M.L. The Biochemical Basis of Phagocytosis. J. Biol. Chem. 1959, 234, 1355-1362.
34. Warburg, O.; Wind, F.; Negelein, E.I. Killing-Off of Tumor Cells in vitro. J. Gen. Physiol. 1927, 8, 519-530. [CrossRef] [PubMed]
35. Hard, G.C. Some biochemical aspects of the immune macrophage. Br. J. Exp. Pathol. 1970, 51, 97-105. [PubMed]
36. Palsson-McDermott, E.M.; Curtis, A.M.; Goel, G.; Lauterbach, M.A.R.; Sheedy, F.J.; Gleeson, L.E.; van den Bosch, M.W.M.; Quinn, S.R.; Domingo-Fernandez, R.; Johnston, D.G.W.; et al. Pyruvate kinase M2 regulates Hif-1α activity and IL-1β induction and is a critical determinant of the warburg effect in LPS-activated macrophages. Cell Metab. 2015, 21, 65-80. [CrossRef] [PubMed]
37. Jha, A.K.; Huang, S.C.-C.; Sergushichev, A.; Lampropoulou, V.; Ivanova, Y.; Loginicheva, E.; Chmielewski, K.; Stewart, K.M.; Ashall, J.; Everts, B.; et al. Network Integration of Parallel Metabolic and Transcriptional Data Reveals Metabolic Modules that Regulate Macrophage Polarization. Immunity 2015, 42, 419-430. [CrossRef] [PubMed]
38. Tannahill, G.M.; Curtis, A.M.; Adamik, J.; Palsson-McDermott, E.M.; McGettrick, A.F.; Goel, G.; Frezza, C.; Bernard, N.J.; Kelly, B.; Foley, N.H.; et al. Succinate is an inflammatory signal that induces IL-1β through HIF-1α. Nature 2013, 496, 238-242. [CrossRef] [PubMed]
39. Norata, G.D.; Caligiuri, G.; Chavakis, T.; Matarese, G.; Netea, M.G.; Nicoletti, A.; O'Neill, L.A.J.; Marelli-Berg, F.M. The Cellular and Molecular Basis of Translational Immunometabolism. Immunity 2015, 43, 421-434. [CrossRef] [PubMed]
40. Sadagopan, N.; Li,W.; Roberds, S.L.; Major, T.; Preston, G.M.; Yu, Y.; Tones, M.A. Circulating succinate is elevated in rodent models of hypertension and metabolic disease. Am. J. Hypertens. 2007, 20, 1209-1215. [PubMed]
41. Vats, D.; Mukundan, L.; Odegaard, J.I.; Zhang, L.; Smith, K.L.; Morel, C.R.; Greaves, D.R.; Murray, P.J.; Chawla, A. Oxidative metabolism and PGC-1β attenuate macrophage-mediated inflammation. Cell Metab. 2006, 4, 13-24. [CrossRef] [PubMed]
42. Hardie, D.G. The AMP-activated protein kinase pathway-New players upstream and downstream. J. Cell Sci. 2004, 117, 5479-5487. [CrossRef] [PubMed]
43. Galic, S.; Fullerton, M.D.; Schertzer, J.D.; Sikkema, S.; Marcinko, K.;Walkley, C.R.; Izon, D.; Honeyman, J.; Chen, Z.-P.; van Denderen, B.J.; et al. Hematopoietic AMPK β1 reduces mouse adipose tissue macrophage inflammation and insulin resistance in obesity. J. Clin. Investig. 2011, 121, 4903-4915. [CrossRef] [PubMed]
44. Furukawa, S.; Fujita, T.; Shimabukuro, M.; Iwaki, M.; Yamada, Y.; Nakajima, Y.; Nakayama, O.; Makishima, M.; Matsuda, M.; Shimomura, I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Investig. 2004, 114, 1752-1761. [CrossRef] [PubMed]
45. Wahl, D.R.; Byersdorfer, C.A.; Ferrara, J.L.M.; Opipari, A.W.; Glick, G.D. Distinct metabolic programs in activated T cells: Opportunities for selective immunomodulation. Immunol. Rev. 2012, 249, 104-115. [CrossRef] [PubMed]
46. Wang, R.; Green, D.R. Metabolic reprogramming and metabolic dependency in T cells. Immunol. Rev. 2012, 249, 14-26. [CrossRef] [PubMed]
47. Mayer, A.; Denanglaire, S.; Viollet, B.; Leo, O.; Andris, F. AMP-activated protein kinase regulates lymphocyte responses to metabolic stress but is largely dispensable for immune cell development and function. Eur. J. Immunol. 2008, 38, 948-956. [CrossRef] [PubMed]
48. Lord, G.M.; Matarese, G.; Howard, J.K.; Baker, R.J.; Bloom, S.R.; Lechler, R.I. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 1998, 394, 897-901. [PubMed]
49. Lee, J.; Walsh, M.C.; Hoehn, K.L.; James, D.E.; Wherry, E.J.; Choi, Y. Regulator of Fatty Acid Metabolism, Acetyl Coenzyme A Carboxylase 1, Controls T Cell Immunity. J. Immunol. 2014, 192, 3190-3199. [CrossRef] [PubMed]
50. Knowler, W.C.; Barrett-Connor, E.; Fowler, S.E.; Hamman, R.F.; Lachin, J.M.; Walker, E.A.; Nathan, D.M. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 2002, 346, 393-403. [PubMed]
51. Gauthier, M.-S.; O'Brien, E.L.; Bigornia, S.; Mott, M.; Cacicedo, J.M.; Xu, X.J.; Gokce, N.; Apovian, C.; Ruderman, N. Decreased AMP-activated protein kinase activity is associated with increased inflammation in visceral adipose tissue and with whole-body insulin resistance in morbidly obese humans. Biochem. Biophys. Res. Commun. 2011, 404, 382-387. [CrossRef] [PubMed]
52. Cacicedo, J.M.; Yagihashi, N.; Keaney, J.F.; Ruderman, N.B.; Ido, Y. AMPK inhibits fatty acid-induced increases in NF-kappaB transactivation in cultured human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun. 2004, 324, 1204-1209. [CrossRef] [PubMed]
53. Yang, Z.; Kahn, B.B.; Shi, H.; Xue, B.Z. Macrophageα1 AMP-activated protein kinase (α1AMPK) antagonizes fatty acid-induced inflammation through SIRT1. J. Biol. Chem. 2010, 285, 19051-19059. [CrossRef] [PubMed]
54. Bechmann, L.P.; Hannivoort, R.A.; Gerken, G.; Hotamisligil, G.S.; Trauner, M.; Canbay, A. The interaction of hepatic lipid and glucose metabolism in liver diseases. J. Hepatol. 2012, 56, 952-964. [CrossRef] [PubMed]
55. DeFronzo, R.A. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: The missing links. The Claude Bernard Lecture 2009. Diabetologia 2010, 53, 1270-1287. [CrossRef] [PubMed]
56. Unger, R.H.; Orci, L. Lipotoxic diseases of nonadipose tissues in obesity. Int. J. Obes. Relat. Metab. Disord. 2000, 24, S28-S32. [CrossRef] [PubMed]
57. Tovar, A.R.; Torres, N. The role of dietary protein on lipotoxicity. Biochim. Biophys. Acta 2010, 1801, 367-371. [CrossRef] [PubMed]
58. Trauner, M.; Arrese, M.;Wagner, M. Fatty liver and lipotoxicity. Biochim. Biophys. Acta 2010, 1801, 299-310. [CrossRef] [PubMed]
59. Samuel, V.T.; Petersen, K.F.; Shulman, G.I. Lipid-induced insulin resistance: Unravelling the mechanism. Lancet 2010, 375, 2267-2277. [CrossRef]
60. Cai, D.; Yuan, M.; Frantz, D.F.; Melendez, P.A.; Hansen, L.; Lee, J.; Shoelson, S.E. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat. Med. 2005, 11, 183-190. [CrossRef] [PubMed]
61. Klover, P.J.; Zimmers, T.A.; Koniaris, L.G.; Mooney, R.A. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 2003, 52, 2784-2789. [CrossRef] [PubMed]
62. Neuschwander-Tetri, B.A. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites. Hepatology 2010, 52, 774-788. [CrossRef] [PubMed]
63. Bettermann, K.; Hohensee, T.; Haybaeck, J. Steatosis and steatohepatitis: Complex disorders. Int. J. Mol. Sci. 2014, 15, 9924-9944. [CrossRef] [PubMed]
64. Jarrar, M.H.; Baranova, A.; Collantes, R.; Ranard, B.; Stepanova, M.; Bennett, C.; Fang, Y.; Elariny, H.; Goodman, Z.; Chandhoke, V.; et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2008, 27, 412-421. [CrossRef] [PubMed]
65. Petersen, K.F.; Dufour, S.; Befroy, D.; Lehrke, M.; Hendler, R.E.; Shulman, G.I. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 2005, 54, 603-608. [CrossRef] [PubMed]
66. DeFronzo, R.A.; Tripathy, D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care 2009, 32, S157-S163. [CrossRef] [PubMed]
67. Savage, D.B.; Petersen, K.F.; Shulman, G.I. Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol. Rev. 2007, 87, 507-520. [CrossRef] [PubMed]
68. Pan, D.A.; Lillioja, S.; Kriketos, A.D.; Milner, M.R.; Baur, L.A.; Bogardus, C.; Jenkins, A.B.; Storlien, L.H. Skeletal Muscle Triglyceride Levels Are Inversely Related to Insulin Action. Diabetes 1997, 46, 983-988. [CrossRef] [PubMed]
69. Roden, M.; Price, T.B.; Perseghin, G.; Petersen, K.F.; Rothman, D.L.; Cline, G.W.; Shulman, G.I. Mechanism of free fatty acid-induced insulin resistance in humans. J. Clin. Investig. 1996, 97, 2859-2865. [CrossRef] [PubMed]
70. Boden, G. Role of Fatty Acids in the Pathogenesis of Insulin Resistance and NIDDM. Diabetes 1997, 46, 3-10. [CrossRef] [PubMed]
71. Schmitz-Peiffer, C.; Craig, D.L.; Biden, T.J. Ceramide Generation Is Sufficient to Account for the Inhibition of the Insulin-stimulated PKB Pathway in C2C12 Skeletal Muscle Cells Pretreated with Palmitate. J. Biol. Chem. 1999, 274, 24202-24210. [CrossRef] [PubMed]
72. Dresner, A.; Laurent, D.; Marcucci, M.; Griffin, M.E.; Dufour, S.; Cline, G.W.; Slezak, L.A.; Andersen, D.K.; Hundal, R.S.; Rothman, D.L.; et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J. Clin. Investig. 1999, 103, 253-259. [CrossRef] [PubMed]
73. Itani, S.I.; Ruderman, N.B.; Schmieder, F.; Boden, G. Lipid-Induced Insulin Resistance in Human Muscle Is Associated With Changes in Diacylglycerol, Protein Kinase C, and IκB-α. Diabetes 2002, 51, 2005-2011. [CrossRef] [PubMed]
74. Hommelberg, P.P.H.; Plat, J.; Langen, R.C.J.; Schols, A.M.W.J.; Mensink, R.P. Fatty acid-induced NF-kappaB activation and insulin resistance in skeletal muscle are chain length dependent. Am. J. Physiol. Endocrinol.Metab. 2009, 296, E114-E120. [CrossRef] [PubMed]
75. Adams, J.M.; Pratipanawatr, T.; Berria, R.; Wang, E.; DeFronzo, R.A.; Sullards, M.C.; Mandarino, L.J. Ceramide Content Is Increased in Skeletal Muscle From Obese Insulin-Resistant Humans. Diabetes 2003, 53, 25-31. [CrossRef]
76. Proud, C.G. Regulation of protein synthesis by insulin. Biochem. Soc. Trans. 2006, 34, 213-216. [CrossRef] [PubMed]
77. Stephens, F.B.; Chee, C.; Wall, B.T.; Murton, A.J.; Shannon, C.E.; van Loon, L.J.C.; Tsintzas, K. Lipid-induced insulin resistance is associated with an impaired skeletal muscle protein synthetic response to amino acid ingestion in healthy young men. Diabetes 2015, 64, 1615-1620. [CrossRef] [PubMed]
78. Guillet, C.; Delcourt, I.; Rance, M.; Giraudet, C.; Walrand, S.; Bedu, M.; Duche, P.; Boirie, Y. Changes in basal and insulin and amino acid response of whole body and skeletal muscle proteins in obese men. J. Clin. Endocrinol. Metab. 2009, 94, 3044-3050. [CrossRef] [PubMed]
79. Masgrau, A.; Mishellany-Dutour, A.; Murakami, H.; Beaufrère, A.-M.;Walrand, S.; Giraudet, C.; Migné, C.; Gerbaix, M.; Metz, L.; Courteix, D.; et al. Time-course changes of muscle protein synthesis associated with obesity-induced lipotoxicity. J. Physiol. 2012, 590, 5199-5210. [CrossRef] [PubMed]
80. Bensellam, M.; Laybutt, D.R.; Jonas, J.-C. The molecular mechanisms of pancreatic β-cell glucotoxicity: Recent findings and future research directions. Mol. Cell. Endocrinol. 2012, 364, 1-27. [CrossRef] [PubMed]
81. Fex, M.; Nitert, M.D.; Wierup, N.; Sundler, F.; Ling, C.; Mulder, H. Enhanced mitochondrial metabolism may account for the adaptation to insulin resistance in islets from C57BL/6J mice fed a high-fat diet. Diabetologia 2007, 50, 74-83. [CrossRef] [PubMed]
82. Poitout, V.; Amyot, J.; Semache, M.; Zarrouki, B.; Hagman, D.; Fontés, G. Glucolipotoxicity of the pancreatic beta cell. Biochim. Biophys. Acta 2010, 1801, 289-298. [CrossRef] [PubMed]
83. Robertson, R.P.; Harmon, J.; Tran, P.O.; Tanaka, Y.; Takahashi, H. Glucose Toxicity in β-Cells: Type 2 Diabetes, Good Radicals Gone Bad, and the Glutathione Connection. Diabetes 2003, 52, 581-587. [CrossRef] [PubMed]
84. Robertson, R.P.; Harmon, J.; Tran, P.O.T.; Poitout, V. β-Cell Glucose Toxicity, Lipotoxicity, and Chronic Oxidative Stress in Type 2 Diabetes. Diabetes 2004, 53, S119-S124. [CrossRef] [PubMed]
85. Maedler, K.; Oberholzer, J.; Bucher, P.; Spinas, G.A.; Donath, M.Y. Monounsaturated Fatty Acids Prevent the Deleterious Effects of Palmitate and High Glucose on Human Pancreatic β-Cell Turnover and Function. Diabetes 2003, 52, 726-733. [CrossRef] [PubMed]
86. El-Assaad,W.; Buteau, J.; Peyot, M.-L.; Nolan, C.; Roduit, R.; Hardy, S.; Joly, E.; Dbaibo, G.; Rosenberg, L.; Prentki, M. Saturated fatty acids synergize with elevated glucose to cause pancreatic beta-cell death. Endocrinology 2003, 144, 4154-4163. [CrossRef] [PubMed]
87. Itoh, Y.; Kawamata, Y.; Harada, M.; Kobayashi, M.; Fujii, R.; Fukusumi, S.; Ogi, K.; Hosoya, M.; Tanaka, Y.; Uejima, H.; et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 2003, 422, 173-176. [CrossRef] [PubMed]
88. Masters, S.L.; Dunne, A.; Subramanian, S.L.; Hull, R.L.; Tannahill, G.M.; Sharp, F.A.; Becker, C.; Franchi, L.; Yoshihara, E.; Chen, Z.; et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat. Immunol. 2010, 11, 897-904. [CrossRef] [PubMed]
89. Youm, Y.-H.; Adijiang, A.; Vandanmagsar, B.; Burk, D.; Ravussin, A.; Dixit, V.D. Elimination of the NLRP3-ASC inflammasome protects against chronic obesity-induced pancreatic damage. Endocrinology 2011, 152, 4039-4045. [CrossRef] [PubMed]
90. World Health Organization. Obesity and Overweight Factsheet. Available online: http://www.who.int/ mediacentre/factsheets/fs311/en/ (accessed on 20 January 2016).
91. Lan, J.; Zhao, Y.; Dong, F.; Yan, Z.; Zheng, W.; Fan, J.; Sun, G. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J. Ethnopharmacol. 2015, 161, 69-81. [CrossRef] [PubMed]
92. Yki-Järvinen, H. Thiazolidinediones. N. Engl. J. Med. 2004, 351, 1106-1118. [CrossRef] [PubMed]
93. Hotamisligil, G.S. Role of endoplasmic reticulum stress and c-Jun NH2-terminal kinase pathways in inflammation and origin of obesity and diabetes. Diabetes 2005, 54, S73-S78. [CrossRef] [PubMed]
94. Wang, L.; Waltenberger, B.; Pferschy-Wenzig, E.-M.; Blunder, M.; Liu, X.; Malainer, C.; Blazevic, T.; Schwaiger, S.; Rollinger, J.M.; Heiss, E.H.; et al. Natural product agonists of peroxisome proliferator-activated receptor gamma (PPAR): A review. Biochem. Pharmacol. 2014, 92, 73-89. [CrossRef] [PubMed]
95. Yuan, M.; Konstantopoulos, N.; Lee, J.; Hansen, L.; Li, Z.W.; Karin, M.; Shoelson, S.E. Reversal of obesityand diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001, 293, 1673-1677. [CrossRef] [PubMed]
96. Shoelson, S.E.; Lee, J.; Goldfine, A.B. Inflammation and insulin resistance. J. Clin. Investig. 2006, 116, 1793-1801. [CrossRef] [PubMed]
97. Kim, J.K.; Kim, Y.; Fillmore, J.J.; Chen, Y.; Moore, I.; Lee, J.; Yuan, M.; Li, Z.W.; Karin, M.; Perret, P.; et al. Prevention of fat-induced insulin resistance by salicylate. J. Clin. Investig. 2001, 108, 437-446. [CrossRef] [PubMed]
98. Hundal, R.S.; Petersen, K.F.; Mayerson, A.B.; Randhawa, P.S.; Inzucchi, S.; Shoelson, S.E.; Shulman, G.I. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J. Clin. Investig. 2002, 109, 1321-1326. [CrossRef] [PubMed]
99. Larsen, C.M.; Faulenbach, M.; Vaag, A.; Vølund, A.; Ehses, J.A.; Seifert, B.; Mandrup-Poulsen, T.; Donath, M.Y. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 2007, 356, 1517-1526. [CrossRef] [PubMed]
100. Kahn, S.E.; Haffner, S.M.; Heise, M.A.; Herman, W.H.; Holman, R.R.; Jones, N.P.; Kravitz, B.G.; Lachin, J.M.; O'Neill, M.C.; Zinman, B.; et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 2006, 355, 2427-2443. [CrossRef] [PubMed]
101. Coll, R.C.; Robertson, A.; Butler, M.; Cooper, M.; O'Neill, L.A.J. The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes. PLoS ONE 2011, 6, e29539. [CrossRef] [PubMed]
102. Feldmann, M. Development of anti-TNF therapy for rheumatoid arthritis. Nat. Rev. Immunol. 2002, 2, 364-371. [CrossRef] [PubMed]
103. Bongartz, T.; Sutton, A.J.; Sweeting, M.J.; Buchan, I.; Matteson, E.L.; Montori, V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295, 2275-2285. [CrossRef] [PubMed]
104. Lim, E.L.; Hollingsworth, K.G.; Aribisala, B.S.; Chen, M.J.; Mathers, J.C.; Taylor, R. Reversal of type 2 diabetes: Normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 2011, 54, 2506-2514. [CrossRef] [PubMed]
105. Borges, R.L.; Ribeiro-Filho, F.F.; Carvalho, K.M.B.; Zanella, M.T. Impact of weight loss on adipocytokines, C-reactive protein and insulin sensitivity in hypertensive women with central obesity. Arq. Bras. Cardiol. 2007, 89, 409-414. [PubMed]
106. Tuomilehto, J.; Lindström, J.; Eriksson, J.G.; Valle, T.T.; Hämäläinen, H.; Ilanne-Parikka, P.; Keinänen-Kiukaanniemi, S.; Laakso, M.; Louheranta, A.; Rastas, M.; et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 2001, 344, 1343-1350. [CrossRef] [PubMed]
107. Kanat, M.; DeFronzo, R.A.; Abdul-Ghani, M.A. Treatment of prediabetes. World J. Diabetes 2015, 6, 1207-1222. [PubMed]
108. Baggio, L.L.; Drucker, D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132, 2131-2157. [CrossRef] [PubMed]
109. Pi-Sunyer, X.; Astrup, A.; Fujioka, K.; Greenway, F.; Halpern, A.; Krempf, M.; Wilding, J.P.H. A Randomized, Controlled Trial of 3.0 mg of Liraglutide inWeight Management. N. Engl. J. Med. 2015, 373, 11-22. [CrossRef] [PubMed]
110. Muscelli, E.; Mingrone, G.; Camastra, S.; Manco, M.; Pereira, J.A.; Pareja, J.C.; Ferrannini, E. Differential effect of weight loss on insulin resistance in surgically treated obese patients. Am. J. Med. 2005, 118, 51-57. [CrossRef] [PubMed]
111. Chrysohoou, C.; Panagiotakos, D.B.; Pitsavos, C.; Das, U.N.; Stefanadis, C. Adherence to the Mediterranean diet attenuates inflammation and coagulation process in healthy adults: The ATTICA Study. J. Am. Coll. Cardiol. 2004, 44, 152-158. [CrossRef] [PubMed]
112. Vessby, B.; Uusitupa, M.; Hermansen, K.; Riccardi, G.; Rivellese, A.A.; Tapsell, L.C.; Nälsén, C.; Berglund, L.; Louheranta, A.; Rasmussen, B.M.; et al. Substituting dietary saturated for monounsaturated fat impairs insulin sensitivity in healthy men and women: The KANWU study. Diabetologia 2001, 44, 312-319. [CrossRef] [PubMed]
113. Tierney, A.C.; McMonagle, J.; Shaw, D.I.; Gulseth, H.L.; Helal, O.; Saris, W.H.M.; Paniagua, J.A.; Gołąbek-Leszczyñska, I.; Defoort, C.; Williams, C.M.; et al. Effects of dietary fat modification on insulin sensitivity and on other risk factors of the metabolic syndrome-LIPGENE: A European randomized dietary intervention study. Int. J. Obes. 2011, 35, 800-809. [CrossRef] [PubMed]
114. Yubero-Serrano, E.M.; Delgado-Lista, J.; Tierney, A.C.; Perez-Martinez, P.; Garcia-Rios, A.; Alcala-Diaz, J.F.; Lopez-Miranda, J. Insulin resistance determines a differential response to changes in dietary fat modification on metabolic syndrome risk factors: The LIPGENE study. Am. J. Clin. Nutr. 2015, 102, 1509-1517. [CrossRef] [PubMed]
115. Oliver, E.; McGillicuddy, F.; Phillips, C.; Toomey, S.; Roche, H.M. The role of inflammation and macrophage accumulation in the development of obesity-induced type 2 diabetes mellitus and the possible therapeutic effects of long-chain n-3 PUFA. Proc. Nutr. Soc. 2010, 69, 232-243. [CrossRef] [PubMed]
116. Pischon, T.; Hankinson, S.E.; Hotamisligil, G.S.; Rifai, N.; Willett, W.C.; Rimm, E.B. Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among US men and women. Circulation 2003, 108, 155-160. [CrossRef] [PubMed]
117. Yang, F.; Oz, H.S.; Barve, S.; de Villiers, W.J.S.; McClain, C.J.; Varilek, G.W. The Green Tea Polyphenol (-)-Epigallocatechin-3-Gallate Blocks Nuclear Factor-kappa B Activation by Inhibiting Ikappa B Kinase Activity in the Intestinal Epithelial Cell Line IEC-6. Mol. Pharmacol. 2001, 60, 528-533. [PubMed]
118. Bose, M.; Lambert, J.D.; Ju, J.; Reuhl, K.R.; Shapses, S.A.; Yang, C.S. The Major Green Tea Polyphenol, (-)-Epigallocatechin-3-Gallate, Inhibits Obesity, Metabolic Syndrome, and Fatty Liver Disease in High-Fat-Fed Mice. J. Nutr. 2008, 138, 1677-1683. [PubMed]
119. Lu, C.-C.; Yen, G.-C. Antioxidative and anti-inflammatory activity of functional foods. Curr. Opin. Food Sci. 2015, 2, 1-8. [CrossRef]
120. Wang, S.; Moustaid-Moussa, N.; Chen, L.; Mo, H.; Shastri, A.; Su, R.; Bapat, P.; Kwun, I.; Shen, C.-L. Novel insights of dietary polyphenols and obesity. J. Nutr. Biochem. 2014, 25, 1-18. [CrossRef] [PubMed]
121. Poulsen, M.M.; Fjeldborg, K.; Ornstrup, M.J.; Kjær, T.N.; Nøhr, M.K.; Pedersen, S.B. Resveratrol and inflammation: Challenges in translating pre-clinical findings to improved patient outcomes. Biochim. Biophys. Acta 2015, 1852, 1124-1136. [CrossRef] [PubMed]
122. Bakker, G.C.; van Erk, M.J.; Pellis, L.; Wopereis, S.; Rubingh, C.M.; Cnubben, N.H.; Kooistra, T.; van Ommen, B.; Hendriks, H.F. An antiinflammatory dietary mix modulates inflammation and oxidative and metabolic stress in overweight men: A nutrigenomics approach. Am. J. Clin. Nutr. 2010, 91, 1044-1059. [CrossRef] [PubMed]